Induction of cytolytic T lymphocytes against pediatric solid tumors in vitro using autologous dendritic cells pulsed with necrotic primary tumor

Shilyansky, Joel; Jacobs, Paulette; Doffek, Kara; Sugg, Sonia L.

doi:10.1016/j.jpedsurg.2006.09.008

Cited by 13 publications

(16 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The vaccine successfully elicited an antitumor response in 7 patients as demonstrated by the detection of tumor-specific cytotoxic T cells. Importantly, the patient's cells recognized metastatic tumor as well [16].…”

Section: Solid Tumorsmentioning

confidence: 97%

“…Much less has been done in tumor antigen discovery using pediatric cancers. The few studies that were performed report that pediatric tumors, as would be expected, express many tumor antigens [8,[10][11][12][13][14][15][16][17] that could be candidate targets for immunotherapy or useful antigens in cancer vaccines. This new effort is welcome since using well-defined antigens is likely to provide useful information regarding the potential of eliciting an anti-tumor immune response in a pediatric cancer patient.…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Cancer Vaccines: Emphasis on Pediatric Cancers

Guinipero¹,

Finn²

2010

CPD

View full text Add to dashboard Cite

The success that vaccines have had in the fight with infectious diseases has not been mirrored in their use in the fight against cancer. The major differences are that cancer vaccines have been tested in the therapeutic rather than the prophylactic setting, and in older adults rather than in the pediatric population. Cancers, as well as current standard treatments, are highly immunosuppressive, which further compromises the success of therapeutic vaccines. Cancer is considered to be primarily a disease of the older age and yet many children suffer from or succumb to cancers such as leukemias, glioblastomas, neuroblastomas and sarcomas. Standard therapy, even when curative, is accompanied by serious side effects, including secondary tumors later in life. Due to the greater capacity of a young immune system to recover after cancer treatment, therapeutic vaccines are expected to have a better chance to elicit protective immunity and prevent cancer recurrence in children. In this review, we discuss the current efforts at designing and testing cancer vaccines in children with the focus on specific tumor antigens expressed by pediatric cancers.

show abstract

Section: Solid Tumorsmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 98%

Cancer Vaccines: Emphasis on Pediatric Cancers

Guinipero¹,

Finn²

2010

CPD

View full text Add to dashboard Cite

show abstract

“…Autologous tumor protein lysates have been used widely in pediatric DC immunotherapy. 5,[7][8][9][10][11]13,14 Strengths of this approach include that fact that lysate is a reliable source of tumor antigen, particularly in tumors for which antigens have been poorly characterized. However, tumor tissue must be obtained, which limits this approach to those with measurable and resectable disease.…”

Section: Antigen Selection and Loadingmentioning

confidence: 99%

“…Clinical responses to DC vaccines in children with malignant solid tumors have been disappointing to date, with excellent tolerability but poor efficacy both in high grade CNS tumors [5][6][7] and in a more diverse group of recurrent solid tumors. 3,[8][9][10][11][12][13][14] Each step of DC vaccine production (see Fig. 1), DC generation, antigen loading, in vitro maturation, and inoculation with or without adjuvant is an opportunity to enhance efficacy.…”

mentioning

confidence: 99%

Dendritic cell vaccines: A review of recent developments and their potential pediatric application

Elster

Krishnadas

Lucas

2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

For many cancers the use of conventional chemotherapy has been maximized, and further intensification of chemotherapy generally results in excess toxicity with little long-term benefit for cure. Many tumors become resistant to chemotherapy, making the investigation of novel approaches such as immunotherapy of interest. Because the tumor microenvironment is known to promote immune tolerance and down regulate the body's natural defense mechanisms, modulating the immune system with the use of dendritic cell (DC) therapy is an attractive approach. Thousands of patients with diverse tumor types have been treated with DC vaccines. While antigen specific immune responses have been reported, the duration and magnitude of these responses are typically weak, and objective clinical responses have been limited. DC vaccine generation and administration is a multi-step process with opportunities for improvement in source of DC for vaccine, selection of target antigen, and boosting effector cell response via administration of vaccine adjuvant or concomitant pharmacologic immunomodulation. In this review we will discuss recent developments in each of these areas and highlight elements that could be moved into pediatric clinical trials.

show abstract

“…Likewise, using PB from NB patients, Shilyansky et al generated functional DCs that were then pulsed with UV-B-treated tumor lysates. Such DCs could prime autologous (i.e., patient derived) antigen-specific, cytotoxic T lymphocytes capable of killing autologous primary and metastatic malignant NB cells (Shilyansky et al 2007). Tolerance to self antigens (including tumor antigens) is well described.…”

Section: Tumor Pulsed Dcsmentioning

confidence: 99%

Recent Developments in Cell-based Immune Therapy for Neuroblastoma

Verneris

Wagner

2007

Jrnl Neuroimmune Pharm

View full text Add to dashboard Cite

Neuroblastoma (NB) is a common and aggressive tumor of early childhood. To date, treatment with chemotherapy, surgery, and radiation therapy has resulted in suboptimal outcomes in those with advanced disease. Immune-based treatments hold promise for patients with recurrent or advanced NB. Here, recent preclinical studies and early stage (phase I) clinical trials using cellular therapeutic approaches for NB are reviewed, including studies of natural killer cells, gammadelta T cells, chimeric receptor expressing T cells, dendritic cells, and allogeneic hematopoietic cell transplant.

show abstract

Induction of cytolytic T lymphocytes against pediatric solid tumors in vitro using autologous dendritic cells pulsed with necrotic primary tumor

Cited by 13 publications

References 54 publications

Cancer Vaccines: Emphasis on Pediatric Cancers

Cancer Vaccines: Emphasis on Pediatric Cancers

Dendritic cell vaccines: A review of recent developments and their potential pediatric application

Recent Developments in Cell-based Immune Therapy for Neuroblastoma

Contact Info

Product

Resources

About